News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Elevance Health's CEO, Gail Boudreaux, purchased $1 million worth of company stock following a decline in share price after the health insurer's second-quarter earnings report. This marks her first stock acquisition for the year.
Sharemaestro market context Trend signal active 52 weeks +10.5% · Next-week setup negative 25.9%Ramiro Peru, a Director at Elevance Health Inc (ELV), recently purchased 1,000 shares, increasing his total holdings to 10,908 shares. This transaction follows a pattern of insider buying within the company, which has seen five insider buys and five insider sells over the past …
Elevance Health reported a strong quarter with raised profit forecasts, yet its stock plunged 8.5% due to significant issues in its Medicaid division. The company is facing a negative Medicaid operating margin and plans to exit several Medicaid markets, indicating a strategic retreat from …
Ramiro G. Peru, a director at Elevance Health, Inc. (NYSE:ELV), recently purchased 1,000 shares of the company's common stock for $366.05 per share, totaling $366,050. This transaction occurred on July 17, 2026, and increased his direct ownership to 10,908 shares. The purchase follows a …
Elevance Health CEO Gail Boudreaux recently purchased 2,725 shares of the company's stock for approximately $1 million, increasing her total equity stake by 2%. This insider purchase is seen as a bullish signal for the company's 2026 outlook, especially in light of positive trends …
Ramiro G Peru, a director at Elevance Health (NYSE: ELV), purchased 1,000 shares of common stock at $366.05 per share on July 17, 2026. This transaction increased his direct ownership to 10,908 shares. The Form 4 filing indicates this was a direct purchase and …
Sharemaestro market context Trend signal active 52 weeks +29.2% · Next-week setup positive 55.7%Elevance Health Inc., parent company of Anthem and Wellpoint, is withdrawing from the Washington D.C. Medicaid market and plans to exit other states by the end of next year. This decision is driven by a portfolio assessment focused on "long-term financial sustainability," as the …
Elevance Health CEO Gail Boudreaux reported purchasing 2,725 shares of the company's common stock on July 17, 2026, across two transactions at weighted-average prices of $366.41 and $368.25. These purchases increased her direct holdings to 171,976 shares, with an additional 60 shares held indirectly. …
Bernstein has increased its price target for Elevance Health (ELV) to $488 from $482, while reiterating an Outperform rating on the stock. This adjustment suggests a positive outlook on the company's future performance.
Leerink Partners adjusted its price target on Elevance Health (NYSE: ELV) to $395, up from $364, while reaffirming a Market Perform rating on the stock. This revision reflects the analyst's updated valuation for the healthcare company.
A strong second quarter by Elevance Health has led Truist to increase its estimates for the company's performance in 2026 and 2027. This positive revision by Truist reflects confidence in Elevance Health's financial outlook following the robust Q2 results.
Elevance Health's Q2 earnings call highlighted growth levers despite Medicaid and high-cost service pressures, with management expressing confidence in returning to double-digit EPS growth by 2027. The company beat earnings expectations, raised its 2026 EPS guidance, and outlined strategies including improving Medicare Advantage economics, …
Elevance Health Inc. (ELV) stock declined by 4.48% on Thursday, closing at $372.85, amidst a general downturn in the stock market where the S&P 500 Index and Dow Jones Industrial Average also fell. This marks the second consecutive day of losses for Elevance Health …
RBC Capital Markets has reduced its price target for Elevance Health (ELV) to $424 from $439, while maintaining a Sector Perform rating on the stock. This adjustment comes despite the firm keeping its rating, indicating a revised outlook on the company's valuation.
Elevance Health (ELV) stock sharply declined despite beating revenue estimates and raising its full-year guidance. The market reacted negatively due to a significant drop in operating margins, particularly in its core Health Benefits segment, driven by higher medical costs in government businesses. Management views …
Sharemaestro market context Trend signal active 52 weeks +10.5% · Next-week setup negative 25.9%Elevance Health's stock is performing strongly, yet its large Medicaid division is a significant drag due to an unprofitable operating margin. The company's strategy includes exiting some Medicaid markets, which, while mitigating losses, also shrinks its revenue base and addressable market. This presents a …
Following its Q2 earnings report, Elevance Health (NYSE: ELV) exceeded analyst expectations, prompting several analysts to revise their forecasts. The company reported adjusted earnings of $7.45 per share and revenue of $49.83 billion, both above consensus estimates, leading to a raised full-year guidance for …
Baird has adjusted its price target for Elevance Health (ELV) to $393, up from $331, while reiterating a Neutral rating on the stock. This update reflects a change in the analyst's valuation for the health insurance company. The article also lists several other firms …
Elevance Health reported stronger-than-expected Q2 results and raised its full-year guidance, leading to a positive market reaction. The company plans to exit underperforming Medicaid markets while focusing on expanding Medicare Advantage and Carelon health services, signaling a shift in its capital allocation and operational …
Elevance Health announced strong results for the second quarter of 2026, with earnings per share and adjusted earnings per share exceeding expectations. The company also reported significant revenue growth and raised its full-year guidance for 2026, indicating continued positive momentum.
Elevance Health is reducing its Medicaid business, exiting the Washington D.C. market effective August 1, and plans to leave additional challenging Medicaid markets over the next 18 months, executives announced. This decision stems from struggles to achieve sustainable performance due to low state payment …
Elevance Health reported Q2 2025 operating revenue of $49.4 billion, a 14.3% year-over-year increase, driven by higher premium yields and Medicare Advantage growth, but net income decreased by 24.2% to $1.74 billion due to elevated medical costs. The company revised its full-year 2025 adjusted …
Shares of Elevance Health Inc. (ELV) fell by 8.54% on Wednesday, closing at $390.33, despite a positive trading session for the broader stock market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains, but Elevance Health's stock performance snapped a …
Elevance Health reported Q2 2026 revenues of $50,474 million, up slightly from the previous year, but shareholder net income declined to $1,463 million due to expenses growing faster than revenue. Diluted EPS for the quarter was $6.71, down from $7.72. The company also announced …
Sharemaestro market context Trend signal active 52 weeks +29.2% · Next-week setup positive 55.7%Elevance Health, Inc. reported its second-quarter 2026 results, showing total revenue of $50.47 billion, a modest increase year-over-year, while diluted EPS declined to $6.71. The company experienced an increase in operating revenue due to premium rate adjustments and growth in CarelonRx, despite a decrease …
Elevance Health, a major licensee of the Blue Cross Blue Shield brand in 14 states, is working to improve its margins despite immediate challenges. The company holds a strong market position, insuring about one-third of the population in its licensed states, which aids in …
Elevance Health's stock is sinking despite beating Q2 earnings estimates and raising full-year guidance. Investors were reportedly underwhelmed as the guidance increase was smaller than the quarterly earnings beat, leading to a broader selloff among managed-care insurers. Elevated medical costs in government businesses also …
Elevance Health Inc. (ANTM) announced its Q2 2026 financial results, reporting adjusted diluted EPS of $7.45 and revenue of $49.83 billion, an increase of 0.8% year-over-year. The company's net income reached $1.62 billion, with medical membership totaling 44,949,000. For the next quarter, Elevance Health …
Elevance Health, Inc. (ELV) reported an adjusted EPS of $7.45 per share for Q2 2026. The company also announced Q2 revenue of $49.83 billion, surpassing the FactSet estimated $48.84 billion, and raised its full-year adjusted EPS outlook. Following these results, several analysts adjusted their …
Elevance Health (NYSE:ELV) exceeded Wall Street's revenue and adjusted EPS expectations in Q2 CY2026, with sales up 2.1% year-on-year to $50.47 billion and non-GAAP profit of $7.45 per share. Despite a decrease in customer numbers, the company's operating margin significantly improved, and management slightly …
Elevance Health has increased its annual profit forecast after exceeding second-quarter earnings expectations. This positive outlook is attributed to the company's effective medical cost management strategies. The insurer also reported a better-than-expected medical loss ratio, indicating efficient spending on medical care.
Elevance Health reported strong Q2 2026 earnings, surpassing expectations with a non-GAAP EPS of $7.45 and revenue of $49.83 billion. The company also upgraded its full-year 2026 diluted EPS and operating cash flow guidance, indicating a positive outlook. Analysts largely maintain optimistic ratings, with …
Elevance Health reported strong Q2 2026 results, with operating revenue reaching $49.8 billion and adjusted diluted EPS of $7.45. The company has raised its full-year 2026 guidance, projecting at least $20.10 diluted EPS and $27.00 adjusted diluted EPS, citing positive benefit expense performance and …
Elevance Health reported strong Q2 2026 results, exceeding expectations with operating revenue of $49.8 billion. The company raised its full-year 2026 diluted EPS guidance to at least $20.10 and adjusted diluted EPS guidance to at least $27.00, along with increasing operating cash flow guidance …
Elevance Health Inc. has raised its annual profit guidance for the second consecutive quarter, signaling a positive trend for the health insurance industry amidst recent federal policy adjustments. The company now forecasts full-year adjusted earnings of at least $27 per share, an increase from …
Elevance Health Inc. reported Q2 results that exceeded analyst expectations for adjusted EPS and revenue. However, shares fell more than 9% premarket due to concerns over declining operating margins, which dropped to 3.5% from 4.9% in the prior year quarter. Despite this, the company …
Search by ticker symbol or company name and select a result to open its chart.